Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00227968 · ClinicalTrials.gov registry record · Phase 4
Psychosocial Therapy Plus Maintenance Pharmacotherapy for Treating Bipolar Disorder
A Phase 4 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 4
- Development phase
- 181
- Enrollment target
NCT00227968: Completed Phase 4 study, sponsored by University of Pittsburgh.
NCT00227968 is a Phase 4 study that has completed, run by University of Pittsburgh. The registered enrollment target is 181 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00227968, a Phase 4 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 181 participants
- Enrollment target
Study Summary
This study will evaluate the effectiveness of interpersonal and social rhythm therapy (IPSRT) versus clinical status and symptom response therapy (CSSRT) in reinforcing the treatment of bipolar disorder in individuals who are currently undergoing medication treatment for the disorder.
Interventions
- BEHAVIORAL Interpersonal Social Rhythm Therapy (IPSRT)
- BEHAVIORAL Clinical Status and Symptom Response Therapy (CSSRT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 1995-03 |
| Est. Completion | 2002-04 |
| Phase | Phase 4 |
What the finished NCT00227968 record still lists
NCT00227968 is an interventional study that assigns participants to a tested intervention. The registered 181 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 2 interventions - of which Interpersonal Social Rhythm Therapy (IPSRT) is the first listed.
NCT00227968 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00227968 about?
NCT00227968 is a clinical study titled "Psychosocial Therapy Plus Maintenance Pharmacotherapy for Treating Bipolar Disorder". This study will evaluate the effectiveness of interpersonal and social rhythm therapy (IPSRT) versus clinical status and symptom response therapy (CSSRT) in reinforcing the treatment of bipolar disorder in individuals who are currently undergoing medication treatment for the disorder.
What is the current status of trial NCT00227968?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 181 participants. The study started on 1995-03. Estimated completion is 2002-04.
What interventions are being tested in trial NCT00227968?
The interventions under investigation include: Interpersonal Social Rhythm Therapy (IPSRT) (BEHAVIORAL), Clinical Status and Symptom Response Therapy (CSSRT) (BEHAVIORAL).
Who is sponsoring clinical trial NCT00227968?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00227968's enrollment target sits among peer trials
181 464th of 2000 higher than 1,535 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04578392 · 181 participants · NA
MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's DiseaSe (SPARES)
- NCT05597891 · 181 participants · NA
Endovascular Engineering ENGULF Study
- NCT03897998 · 182 participants · Phase 2
Neural Correlates of Hypoalgesia Driven by Observation
- NCT04300556 · 182 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia